Therapeutic implications of diabetes in cardiovascular disease

American Journal of Therapeutics

Volumn 16, Issue 6, 2009, Pages

  Cherian, Biju ^a   Meka, Naga ^a   Katragadda, Srikanth ^a   Arora, Rohit ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Cardiovascular risk; Inflammation; Insulin resistance; Prediabetes; Thiazolidinediones

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ACETYLSALICYLIC ACID; EXENDIN 4; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; INSULIN; METFORMIN; MIGLITOL; NATEGLINIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PIOGLITAZONE; PLACEBO; REPAGLINIDE; ROSIGLITAZONE; SITAGLIPTIN; SULFONYLUREA; TROGLITAZONE;

ADD ON THERAPY; ATHEROSCLEROSIS; BLINDNESS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC DIET; DIABETIC HYPERTENSION; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC OBESITY; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG WITHDRAWAL; DYSLIPIDEMIA; EDEMA; FLUID RETENTION; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART FAILURE; HEART INFARCTION; HEPATITIS; HUMAN; HYPOGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; INSULIN SENSITIVITY; KINESIOTHERAPY; LIFESTYLE MODIFICATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSICAL ACTIVITY; PREGNANCY DIABETES MELLITUS; PREVALENCE; PRIORITY JOURNAL; RESTENOSIS; REVIEW; RISK ASSESSMENT; SIDE EFFECT; STROKE; TOOTH DISEASE; WEIGHT GAIN; WEIGHT REDUCTION;

ANTI-OBESITY AGENTS; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; EXERCISE; GLUCOSE INTOLERANCE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; LIFE STYLE; PREDIABETIC STATE; RISK FACTORS; WEIGHT LOSS;

EID: 74549218772     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/MJT.0b013e31815db924     Document Type: Review

References (48)

1. American Diabetes Association. Available at: www. diabetes.org/about- diabetes.jsp. Accessed June 10, 2007.
2. National Diabetes Statistics, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH. Available at: diabetes.niddk.nih. gov/dm/pubs/statistics. Accessed June 10, 2007.
3. National Diabetes Fact Sheet, Centers for Disease Control and Prevention. Available at: www.cdc.gov/diabetes/ pubs/pdf/ndfs-2005.pdf. Accessed June 10, 2007.
4. Jeong-A K, Montagnani M, Koh KK, et al. Reciprocal relationships between insulin resistance and endothelial dysfunction. Circulation. 2006;113:1888-1904.
5. De Luca C, Olefsky JM. Stressed out about obesity and insulin resistance. Nat Med. 2006;12:41-42.
6. Kuk JL, Katzmarzyk PT, Nichaman MZ, et al. Visceral fat is an independent predictor of all-cause mortality in men. Obesity. 2006;14:336-341.
7. Després J-P. Abdominal obesity: the most prevalent cause of the metabolic syndrome and related cardiometabolic risk. Eur Heart J. 2006;8(Suppl B):B4-12
8. McFarlane SI, Banerji M, Sowers JR. Insulin resistance and cardiovascular disease. J Clin EndocrinolMetab. 2001;86:713-718.
9. Lau DC, Dhillon B, Yan H. Adipokines: molecular links between obesity and atherosclerosis. Am J Physiol Heart Circ Physiol. 2005;288:H2031-2041.
10. Wellen KE, Hotamisligil GS. Inflammation, stress and diabetes. J Clin Investigation. 2005;115:1111-1119.
11. Pischon T, Girman CJ, Hotamisligil GS, et al. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA. 2004;291:1730-1737.
12. Pajvani UB, Hawkins M, Combs TP, et al. Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biology Chem. 2004;279:12152-12162.
13. Hu FB, Stampfer MJ, Haffner SM, et al. Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabetes Care. 2002;25:1129-1134.
14. DECODE Study. Glucose tolerance and mortality. Lancet. 1999;354:617-621.
15. Brunner EJ, Shipley MJ, Witte DR, et al. Whitehall Study. Relation between blood glucose and coronary mortality. Diabetes Care. 2006;29:26-31.
16. Norhammar A, Tenerz A, Nilsson GH, et al. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus. A prospective study. Lancet. 2002;359:2140-2144.
17. Matz K, Keresztes K, Tatschl C. Disorders of glucose metabolism in acute stroke patients: an underrecognized problem. Diabetes Care. 2006;29:792-797.
18. Muhlestein JB, Anderson JL, Horne BD. Effect of fasting glucose levels on mortality rate in patients with and without diabetes mellitus and coronary artery disease undergoing percutaneous coronary intervention. Am Heart J. 2003;146:351-358.
19. Caballero AE, Arora S, Saouaf R. Microvascular and macrovascular reactivity is reduced in subjects at risk for type 2 diabetes. Diabetes. 1999;48:1856-1862.
20. Meisner F,Walcher D, Gizard F, et al. Effect of rosiglitazone treatment on plaque inflammation and collagen content in non-diabetic patients, a randomized placebo-controlled trial. Arterioscler Thromb Vasc Biol. 2006;26:845-850.
21. Masoudi FA, Inzucchi SE, Wang Y. Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Circulation. 2005;111:583-590.
22. Minamikawa J, Tanaka S, Yamauchi M, et al. Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab. 1998; 83:1818-1820.
23. Koshiyama H, Shimono D, Kuwamura N, et al. Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab. 2001;86:3452-3456.
24. Langenfeld MR, Forst T, Hohberg C, et al. Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus. Results from a controlled randomized study. Circulation. 2005;111:2525-2531.
25. Sidhu JS, Kaposzta Z, Markus HS, et al. Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes metlitus. Arterioscler Thromb Vasc Biol. 2004;24: 930-934.
26. Choi D, Kim SK, Choi SH. Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes. Diabetes Care. 2004; 27:2654-2660.
27. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (Prospective Pioglitazone Clinical Trial in Macrovascular Events): a randomized controlled trial. Lancet. 2005;366:1279-1289.
28. Buchanan TA, Xiang AH, Peters RK. Preservation of pancreatic B-cell function and prevention of type 2 diabetes. Diabetes. 2002;51:2796-2803.
29. DREAM Trial Investigators. Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention. Diabetologia. 2004;47:1519-1527.
30. DREAM Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet. 2006;368:1096-1105.
31. Kahn SE, Haffner SM, Heise MA. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. ADOPT Study group. N Engl J Med. 2006;355:2427-2443.
32. Viberti G, Kahn SE, Greene DA. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care. 2002;25:1737-1743.
33. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356:2457-2471. (Pubitemid 46919772)
34. Psaty BM, Furberg CD. Rosiglitazone and cardiovascular risk. N Engl J Med. 2007;356:2522-2524.
35. Home PD, Pocock SJ, Beck-Nielsen H, et al. RECORD Study Group. Rosiglitazone evaluated for cardiovascular outcomes-an interim analysis.NEngl JMed. 2007;357:28-38.
36. Rosen CJ. The Rosiglitazone Story, a perspective-lessons from an FDA Advisory Committee Meeting. Available at: www.nejm.org. Accessed August 8, 2007.
37. Mazzone T, Meyer PM, Feinstein SB, et al. Effect of pioglitazone compared with glimepiride on CIMT, CHICAGO Trial. JAMA. 2006;296:2572-2581.
38. DPP Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393-403.
39. Roberts CK, Carey Ng, Hama S, et al. Effect of a shortterm diet and exercise intervention on inflammatory/ anti-inflammatory properties of HDL in overweight/ obese men with cardiovascular risk factors. J Appl Physiol. 2006;100:1727-1732
40. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA. 2002;287:2570-2581.
41. Fang J, Alderman M. Impact of the increasing burden of diabetes on acute myocardial infarction in New York City: 1990-2000. Diabetes. 2006;55:768-773. (Pubitemid 43343234)
42. Nicholls SJ, Tuzcu EM, Crowe T, et al. Relationship between cardiovascular risk factors and atherosclerotic disease burden measured by intravascular ultrasound. J Am Coll Cardiol. 2006;47:1967-1975.
43. Sigal RJ, Kenny GP, Wasserman DH. Physical activity/ exercise and type 2 diabetes: a consensus statement from the American Diabetes Association. Diabetes Care. 2006;29: 1433-1438.
44. Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in diabetics. N Engl J Med. 2003;348:383-393.
45. Costa J, Margarida B, Claudio D, et al. Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomized controlled trials. BMJ. 2006;332:1115-1124.
46. Collins R, Armitage J, Parish S. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomized placebo-controlled trial. Lancet. 2003;361:2005-2016.
47. Malmberg K. Prospective randomized study of intensive insulin treatment on long-term survival after acute myocardial infarction in patients with diabetes mellitus. D1GAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. BMJ. 1997; 314:1512-1515.
48. Furnary AP, Wu Y, Bookin SO. Effect of hyperglycemia and continuous intravenous insulin infusions on outcomes of cardiac surgical procedures: the Portland diabetic project. Endocr Pract. 2004;10(Suppl 2):21-33.